07.06.2013 | Maria Lucia Corrêa-Giannella; Ubiratan F Machado, Pharmacogenomics, 2013

Pharmacogenomics , June 2013, Vol. 14, No. 8, Pages 847-850.

mehr

07.06.2013 | Ana Alfirevic; Daniel F Carr; Fabio Miyajima; Sudeep Pushpakom; Laura Sutton; Andrea L Jorgensen; Munir ..., Pharmacogenomics, 2013

The Wolfson Centre for Personalised Medicine is part of the Institute of Translational Medicine at the University of Liverpool (Liverpool, UK). It houses a multidisciplinary team of personalized medicine researchers engaged in collaborative research with partners across the globe. The primary ...

mehr

07.06.2013 | Fabrice André; Joseph Ciccolini; Jean-Philippe Spano; Frédérique Penault-Llorca; Nicolas Mounier; Gilles ..., Pharmacogenomics, 2013

Current advances in the biology of cancer and emergence of new tools for genome analysis have opened clinical perspectives in oncology, generally termed as ‘personalized medicine’. This broad term must encompass previous well-proven strategies, such as pharmacogenetics- and ...

mehr

07.06.2013 | James J Chen; Wei-Jiun Lin; Hung-Chia Chen, Pharmacogenomics, 2013

Pharmacogenomics examines how the benefits and adverse effects of a drug vary among patients in a target population by analyzing genomic profiles of individual patients. Personalized medicine prescribes specific therapeutics that best suit an individual patient. Much current research focuses ...

mehr

07.06.2013 | Marc Via; Haig Tcheurekdjian; Esteban González Burchard, Pharmacogenomics, 2013

Researchers have identified thousands of loci involved in complex traits and drug response. However, in most cases they only explain a small proportion of the heritability of the trait. Among different strategies conducted to identify this ‘missing heritability’, here we illustrate the ...

mehr

07.06.2013 | Grace M Kuo; Kelly C Lee; Joseph D Ma, Pharmacogenomics, 2013

Aim: This study evaluated the implementation and outcomes of a pharmacogenomics education program among pharmacists. Materials & methods: Continuing education lectures were presented at local, state and national pharmacy conferences. Results: Six hundred and seventy three pharmacist ...

mehr

06.06.2013 | Kyle B Brothers; Matthew J Westbrook; M Frances Wright; John A Myers; Daniel R Morrison; Jennifer L Madi ..., Personalized Medicine, 2013

Aim: In this study, we sought to assess patient awareness and perceptions of an opt-out biorepository. Materials & methods: We conducted exit interviews with adult patients and parents of pediatric patients having their blood drawn as part of their clinical care at Vanderbilt University ...

mehr

06.06.2013 | Reem Alsolami; Samantha JL Knight; Anna Schuh, Personalized Medicine, 2013

Chronic lymphocytic leukemia (CLL) is low-grade lymphoma of mature B cells and it is considered to be the most common type of hematological malignancy in the western world. CLL is characterized by a chronically relapsing course and clinical and biological heterogeneity. Many patients do not ...

mehr

06.06.2013 | Kristin Pothier; Gary Gustavsen, Personalized Medicine, 2013

We are entering an era of unprecedented complexity in personalized medicine. Therapeutic targets, biomarker detection technologies, regulatory and reimbursement pathways, and commercialization strategies have all reached new levels of intricacy. These complexities are occurring in the context ...

mehr

06.06.2013 | Personalized Medicine, 2013

Personalized Medicine , June 2013, Vol. 10, No. 4, Pages 325-327.

mehr